Shenzhen Celestial

Shenzhen Celestial is a biotechnology company based in Shenzhen, China, specializing in the development of advanced cell therapies for oncology. The company focuses on chimeric antigen receptor T-cell (CAR-T) technologies, targeting hematological malignancies such as leukemia and lymphoma. Their research and development efforts are centered on optimizing CAR-T constructs to improve efficacy and safety profiles in clinical settings. Shenzhen Celestial operates a pipeline that includes programs targeting CD19 and BCMA, aiming to provide next-generation treatment options for patients with refractory or relapsed cancers. The company is actively engaged in early-stage clinical trials to validate its therapeutic candidates.